Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial-January 2024-www.financetom.com

Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial

Sep 24, 2025 5:29 AM

Sept 24 (Reuters) - Harmony Biosciences ( HRMY ) said on

Wednesday its experimental drug for a type of rare genetic

disorder failed to meet the main goal in a late-stage trial.

Previous page： Spice maker McCormick beats quarterly results on strong EMEA business Next page： BRIEF-Argonautic Ventures Says Preliminary Non-Binding Proposal To Benson Hill's Board Related To Proposed Acquisition By To-Be-Formed Acquisition Vehicle

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Spice maker McCormick beats quarterly results on strong EMEA business

Jun 27, 2024

(Reuters) - McCormick ( MKC ) beat market expectations for second-quarter profit and sales on Thursday, led by strong demand for its spices and seasonings in Europe, Middle East and Africa. Customers grappling with still-high costs preferred cooking at home to dining out, improving volumes across the company's consumer segment, its biggest unit. Consumer sales in Europe, Middle East and...

BRIEF-Argonautic Ventures Says Preliminary Non-Binding Proposal To Benson Hill's Board Related To Proposed Acquisition By To-Be-Formed Acquisition Vehicle

Jun 27, 2024

June 27 (Reuters) - Benson Hill Inc ( BHIL ): * ARGONAUTIC VENTURES - PRELIMINARY NON-BINDING PROPOSAL TO BENSON HILL'S BOARD RELATED TO PROPOSED ACQUISITION BY TO-BE-FORMED ACQUISITION VEHICLE * ARGONAUTIC VENTURES-PROPOSAL TO BENSON HILL'S BOARD RELATED TO PROPOSED ACQUISITION ALL OF OUTSTANDING SHARES FOR CASH CONSIDERATION OF $0.2236/SHARE Source text for Eikon: Further company coverage: ...

Andlauer Healthcare to Launch Normal Course Issuer Bid

Jun 27, 2024

09:00 AM EDT, 06/27/2024 (MT Newswires) -- Andlauer Healthcare Group ( ANDHF ) said Thursday that it secured TSX approval for a normal course issuer bid (NCIB) for up to 10% of its public float over the next 12 months. The company said it can purchase its shares for cancellation beginning on July 2 and until July 1, 2025. Andlauer...

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

Jun 27, 2024

June 27 (Reuters) - Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday. The U.S. health regulator's assent on Wednesday for the therapy, branded as Ohtuvayre, provides a new inhaled non-steroidal treatment for chronic obstructive pulmonary...